Clinical Study Of Low Molecular Weight Heparin In Preventing Thrombosis In Tumor Patients

OBJECTIVE:Thrombosis is a common complication of tumor.Currently,the clinicaldataarelimitedtosupportthebenefitofprophylactic anticoagulation.Objective to evaluate the efficacy and safety of low molecular weight heparin in the prevention of thrombosis in tumor patients,and to prevent the appropriate population,safe dosage and time of drug use in the prevention of tumor thrombus in patients with tumor.METHODS:This experiment is 1:1 open,diagnostic criteria for the diagnosis of cancer patients with clear,local progression or distant metastases,into the group after randomly divided into treatment group,receiving chemotherapy combination with the administration of enoxaparin anticoagulation,4000iu once daily subcutaneous injection with chemotherapy drug synchronization;control group patients received chemotherapy alone.Not given prophylactic anticoagulation therapy.The primary outcome of the study was to observe the safety and the incidence of thrombosis,and to observe the survival time and survival rate.Establishing database of all clinical data and analysing data by the application of SPSS19.0 statistical software.?~2 test were used to analysis count data.T-test were used to analysis measurement data.Survival curves were plotted used by Kaplan-Meier method,Log-rank test between group differences.RESULTS:In the study,95 patients were enrolled and 86 patients completed the study.The patients were followed up for 3-22 months,of which the treatment group(47 cases)and the control group(39 cases).The incidence of thrombosis in the treatment group was significantly lower than that in the control group,2.13%and25.64%,respectively,and the difference was statistically significant(?~2,5.64;P=0.03).There was no significant difference in the incidence of bleeding events and adverse events between the two groups.To the end of the study,a total of 60 patients were followed up,In the treatment group,the median overall survival was 14 months(10.710-17.290 95%CI),and the median overall survival was 12 months(8.504-15.496 95%CI),and no significant difference(P=0.29)was compared between the two groups;Subgroup analysis,Patients with stage III and IV tumors were significantly longer than those in the control group for 12 months(9.214-14.78695%CI)for 8 months(5.600-10.400 95%CI),P=0.05,and the difference was significant.CONCLUSION:The incidence of low molecular heparin can reduce chemotherapy patients with malignant tumor thrombotic events,relieve the hypercoagulability of patients with malignant tumor,prevention of malignant tumor patients complicated with tumor associated with thromboembolic disease,and there is no increased bleeding and the incidence of adverse events;to extend stage III-IV patients overall survival time,improve in patients with advanced malignant tumor prognosis.